Impact of Stenosis and Plaque Features in Coronary CT Angiography, Physiologic Assessment and Pharmacotherapy on the Clinical Outcomes After Invasive Coronary Angiography
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 992
- 试验地点
- 1
- 主要终点
- Adverse cardiovascular event according to pre-PCI FFR in vessels with low post-PCI FFR (PCI group).
研究概览
简要总结
The investigators aim to investigate the prognostic implication of stenosis and plaque features on coronary CT angiography (CCTA), physiologic assessment, and pharmacotherapy after invasive coronary angiography.
详细描述
Stenosis severity, plaque features, and myocardial ischemia have been known as important indicators in diagnosis and prognostication of patients with coronary artery disease. Invasive physiologic indies such as fractional flow reserve (FFR) are used to define ischemia-causing stenosis in the catheterization laboratory. FFR represents maximal blood flow to the myocardium supplied by an artery with stenosis as a fraction of normal maximum flow. The FFR-guided strategy was reported to improve the patients' outcomes in comparison with the angiography-guided strategy. However, clinical events still occur in patients with FFR >0.80, and invasive therapy did not improve prognosis in patients with moderate to severe ischemia compared to optimal medical therapy in the ISCHEMIA trial. In the recent report, the prognosis in the vessel with FFR >0.80 was associated with high-risk plaque characteristics on coronary CT angiography (CCTA). Likewise, incorporation of stenosis and plaque features and myocardial ischemia may provide better risk stratification of patients with coronary artery disease than evaluating each attribute alone. Recent proposed novel measurement such as pericoronary inflammation or epicardial fat metrics and lesion-specific or vessel-specific hemodynamic parameters derived from CCTA has also been known as a robust prognostic predictor. In addition, antiplatelet agents and lipid-lowering medication such as aspirin, clopidogrel, or statin are commonly used for primary and secondary prevention of adverse cardiovascular events. However, the relationship of combination and dosage of those drugs with prevention of plaque progression and clinical outcomes has not been fully understood. Accordingly, the investigators aim to find the prognostic implications of stenosis and plaque features, fat metrics on CCTA along with physiologic assessment and pharmocotherapy according to the different treatment strategies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 20 years
- •Patients who undergo CCTA within 90 days before FFR measurement by clinical needs
- •Patients with a vessel determined to defer revascularization after FFR measurement.
排除标准
- •Left ventricular ejection fraction < 35%
- •Acute ST-elevation myocardial infarction within 72 hours or previous coronary artery bypass graft surgery
- •Abnormal epicardial coronary flow (TIMI flow < 3)
- •Failed FFR measurement
- •Planned coronary artery bypass graft surgery after diagnostic angiography
- •Poor quality of CCTA which is unsuitable for plaque analysis
- •Patients with a stent in the target vessel
- •PCI group
- •Inclusion Criteria:
- •Age ≥ 20 years
- •Patients who undergo CCTA within 90 days before FFR measurement by clinical needs
- •Patients with a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR).
- •Patients with multiple vessels that meet inclusion criteria of the deferral of PCI group and PCI group will be assigned to the PCI group.
- •Exclusion Criteria:
- •Left ventricular ejection fraction < 35%
- •Acute ST-elevation myocardial infarction within 72 hours or previous coronary artery bypass graft surgery
- •Abnormal epicardial coronary flow (TIMI flow < 3)
- •Failed FFR measurement
- •Planned coronary artery bypass graft surgery after diagnostic angiography
- •Poor quality of CCTA which is unsuitable for plaque analysis
- •Patients with a stent in the target vessel
结局指标
主要结局
Adverse cardiovascular event according to pre-PCI FFR in vessels with low post-PCI FFR (PCI group).
时间窗: Upto 2 years after index procedure
A composite of cardiac death, vessel-related myocardial infarction (MI), or vessel-related ischemia-driven revascularization. The target vessel will be defined as the vessel with FFR measurement.
Adverse cardiovascular event according to stenosis and plaque features (Deferral group).
时间窗: Upto 2 years after index procedure
A composite of cardiac death, vessel-related myocardial infarction (MI), or vessel-related ischemia-driven revascularization. The target vessel will be defined as the vessel with FFR measurement.
次要结局
- Comprehensive risk prediction model by integrating stenosis and plaque features, local hemodynamic parameters (Deferral group).(Upto 2 years after index procedure)
- Risk of adverse cardiovascular events according to pre-PCI FFR (PCI group).(Upto 2 years after index procedure)
- Comprehensive risk prediction model by integrating stenosis and plaque features on CCTA and physiologic assessment before and after PCI (PCI group).(Upto 2 years after index procedure)
- Additive prognostic value of stenosis and plaque features on CCTA over FFR in prediction of adverse cardiovascular events (Deferral group).(Upto 2 years after index procedure)
- Prognostic value of CT-defined pericoronary and epicardial fat metrics (fat attenuation index [FAI], epicardial fat attenuation index [EFAI], and epicardial fat volume [EFV]) (Deferral group).(Upto 2 years after index procedure)
- Prognostic impact of stenosis and plaque features on CCTA, local hemodynamic parameters (PCI group).(Upto 2 years after index procedure)
- Risk prediction model by stenosis and plaque features, local hemodynamic parameters, and fat metrics and physiologic assessment (delta FFR and FFR) (PCI group).(Upto 2 years after index procedure)
- Comparison of risk for future events by comprehensive CCTA analysis and physiologic assessment between the deferral of PCI and PCI group (Whole population).(Upto 2 years after index procedure)
- Clinical events and plaque and physiologic characteristics by medication history including antiplatelet agents and statin and serum lipid level during follow-up (Deferral group).(Upto 2 years after index procedure)
- Risk prediction model by stenosis and plaque features, local hemodynamic parameters, and fat metrics and physiologic assessment (delta FFR and FFR) (Deferral group).(Upto 2 years after index procedure)
- Prognostic value of CT-defined pericoronary and epicardial fat metrics (FAI, EFAI, EFV) (PCI group).(Upto 2 years after index procedure)
- Relationship among FFR values, CT-derived plaque qualification and quantification, and CT-defined pericoronary and epicardial fat metrics including FAI, EFAI, and EFV (Whole population).(Upto 2 years after index procedure)
- Clinical events and plaque and physiologic characteristics by medication history including antiplatelet agents and statin and serum lipid level during follow-up (PCI group).(Upto 2 years after index procedure)
研究者
Bon-Kwon Koo
Professor
Seoul National University Hospital